Related Experiment Video
Updated: Oct 15, 2025
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Optimizing anti-body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision
1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center Houston, Houston, TX.
Abstract:
Drug delivery to select therapeutic targets for precision oncology has always been a major challenge in oncology. Anti-body drug conjugates (ADC) and radiopharmaceuticals attempt to overcome the major limitations of chemotherapy or mono-clonal antibody therapy as they provide a highly specific means of attacking the vulnerability of the cancer cell. Currently there are over 100 clinical trials in various stages of development with these agents. Years of improved understanding of ADC technology and addressing previous failures have yielded the current pipeline of ADCs with better design. The near future of ADC developmental therapeutics includes firstly continuing to improve drug design, secondly picking right targets, thirdly balancing efficacy vs toxicity, fourth understanding innate and acquired resistance mechanisms, fifth development of ADCs across pan-cancers as tissue-agnostic therapeutics, and lastly combination strategies. There is considerable excitement in the ADC developmental therapeutics and ADCs including radiopharmaceuticals are here to stay and offer to expand our pipeline of effective drugs to combat cancer.
Insights
Antibody-drug conjugates (ADCs) and radiopharmaceuticals offer targeted cancer therapy, overcoming chemotherapy limitations. Ongoing advancements promise improved drug design, target selection, and resistance management for broader efficacy.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Precision oncology faces challenges in targeted drug delivery.
- Antibody-drug conjugates (ADCs) and radiopharmaceuticals aim to overcome limitations of traditional chemotherapy and monoclonal antibody therapies.
- These targeted agents offer specific delivery to cancer cell vulnerabilities, with over 100 clinical trials underway.
Discussion:
- Current ADC technology has evolved significantly, addressing past failures and leading to improved designs.
- Key areas for future ADC development include refining drug design, optimizing target selection, and balancing efficacy with toxicity.
- Understanding and overcoming innate and acquired resistance mechanisms is crucial for ADC success.
Key Insights:
- ADCs and radiopharmaceuticals represent a significant advancement in cancer treatment strategies.
- Improved understanding of ADC technology has resulted in a robust pipeline of next-generation agents.
- The development of ADCs across various cancer types as tissue-agnostic therapeutics is a key future direction.
Outlook:
- The future of ADC therapeutics involves enhancing drug design, precise target identification, and managing toxicity.
- Addressing resistance mechanisms and exploring combination strategies will be vital.
- ADCs, including radiopharmaceuticals, are poised to expand the arsenal of effective cancer drugs.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy